ArticleCancer medicine2026
The Preclinical Effects and Mechanisms of Biofield Therapy on Pancreatic Cancer Cell Growth and Metastasis.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe high mortality of pancreatic ductal adenocarcinoma (PDAC) underscores the need for novel treatments. We investigated the potential role of human biofield therapy (BT) in modifying tumorigenic processes in murine and human PDAC cells through a series of in vitro and in vivo studies.
methodsCell viability and ultrastructure changes were examined by PrestoBlue assay and Transmission Electron Microscope, respectively. Cell voltage potentials were assessed using DiBAC4 staining. Both FOXM1 CRISPR KO and Tet-on FOXM1 overexpressing PDAC cells were used for the mechanistic studies. Antitumor efficacy was tested in orthotopic models using human PANC-1 and mouse KPCY cells.
resultsMultiple mouse and human PDAC cell lines exposed to BT (three different therapists using a standardized procedure) showed significantly reduced proliferation compared to sham control (SC) and incubator control (IC) cells across multiple studies. BT induced swollen mitochondria in PANC-1 cells and increased G1 cell cycle arrest in PANC-1, L3.7, and COLO357 cells. BT also downregulated key cell cycle regulators including FOXM1 in PANC-1 and L3.7 cells (p < 0.05). BT led to a 36.7% reduction of cell voltage potential measured in PANC-1 cells (p < 0.01), with similar effects in MiaPaCa-2 and KPCY cells. Furthermore, BT reduced the invasiveness in PANC-1, L3.7, and COLO357 cells, an effect influenced by FOXM1 gene expression. BT inhibited the primary tumor growth and liver metastasis of PANC-1 and KPCY cells in orthotopic mouse models (p < 0.05).
conclusionsThese novel findings support the potential of BT to influence growth and metastasis of pancreatic cancer cells and warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.